27 March 2020 Volume 27 Supplement 1 S1 Volume 27 Volume Supplement 1 A1–A232 Pages EUROPEAN JOURNAL OF HOSPITAL PHARMACY OF HOSPITAL JOURNAL EUROPEAN ABSTRACT BOOK 25th EAHP Congress 25th–27th March 2020 Gothenburg, Sweden March 2020 March CALL FOR ABSTRACTS - 2021 26th Congress of the EAHP, 24-26 March 2021, Vienna, Austria Abstract submission opens 1st August, 2020! Original contributions from all fields of hospital pharmacy are encouraged and welcomed for poster presentation. Deadline for submission: 15th October 2020 During the review process, the award nominees will be selected and the presenting author of the nominated abstracts will be invited to give an oral presentation after which the final judging will take place. Please be sure to provide an email address which will not be blocked by spam servers so that EAHP may notify you for modifications and nominations. (Abstracts may be submitted through the EAHP web site’s online submission page.) IMPORTANT NOTE: The online submission form does not recognise some symbols from certain keyboards. Therefore, please proof your abstract after it has been entered into the system and before your final submission. Please visit the EAHP web site at http://www.eahp.eu/congresses/abstract to view the guidelines and to submit abstracts for the Vienna Congress 2021. Abstracts must be entered into the system by section according to the guidelines. There will be 5 sections: Background - Aim and objectives - Material and methods - Results - Conclusion All abstracts must be linked to the European Statements on Hospital Pharmacy: Section 1: Introductory Statements and Governance Section 2: Selection, Procurement and Distribution Section 3: Production and Compounding Section 4: Clinical Pharmacy Services Section 5: Patient Safety and Quality Assurance Section 6: Education and Research Contents Volume 27 Supplement 1 | EJHP March 2020 Abstracts from the EAHP 2020 Congress A1 Section 1: Introductory Statements and A150 Section 5: Patient Safety and Quality Governance Assurance A9 Section 2: Selection, Procurement and A205 Section 6: Education and Research Distribution A215 National Poster Prize Winners A22 Section 3: Production and Compounding A222 Author Index A47 Section 4: Clinical Pharmacy Services $:$5'120,1((6 3UHVHQWDWLRQVRQ:HGQHVGD\0DUFK±5220) 7LPH 3RVWHUQXPEHU $ZDUGQRPLQHHRUDOSUHVHQWDWLRQV 3UHVHQWLQJDXWKRU +2:08&+'2(6)$/6,),('0(',&,1(6',5(&7,9($&78$//< Section 2 &2676"'(7$,/('&267(9$/8$7,212)6(5,$/,6$7,21,1 10:33 $)LWWOHU 2SPD-023 $5(35(6(17$7,9(6$03/(2)+81*$5,$1+263,7$/ 3+$50$&,(6 Section 3 $872/2*2867,668($'+(6,9(,123+7+$/02/2*,&$/ 10:41 6%HULVD 3PC-032 685*(5< Section 4 '(9(/230(172)$%(/*,$1&/$66,),&$7,216<67(0)25 10:49 3-&RUWRRV 4CPS-168 &/,1,&$/3+$50$&<$&7,9,7,(6 Section 4 &267())(&7,9(1(66$1$/<6,62)0(523(1(0'26( 10:57 $2UWHJD 4CPS-045 237,0,6$7,21,1&5,7,&$/3$7,(176 5,6.)$&7256$662&,$7(':,7+5($'0,66,21727+( Section 4 (0(5*(1&<'(3$570(17,13$7,(176:,7+35(9,286 11:05 //ySH]9LQDUGHOO 4CPS-008 *$6752,17(67,1$/+$(0255+$*(6(&21'$5<7225$/ $17,&2$*8/$177+(5$3< 81'(5'26,1*:,7++,*+'26(3,3(5$&,//,17$=2%$&7$0 Section 4 $'0,1,67(5('9,$&217,18286,1)86,21,12873$7,(17 11:13 &4XLQWHQV 4CPS-049 3$5(17(5$/$17,0,&52%,$/7+(5$3<$67$%,/,7<25 9,6&26,7<352%/(0" )$&,/,7$7256$1'%$55,(56723(5)250,1* Section 4 &2035(+(16,9(0(',&$7,215(9,(:6$1')2//2:83,1 11:21 8*LOOHVSLH 4CPS-174 2/'(5+263,7$/,6('3$7,(176%<08/7,352)(66,21$/ :$5'7($06,1&/8',1*$&/,1,&$/3+$50$&,67 Section 4 7+(81'(55(3257,1*5$7($6$3+$50$&29,*,/$1&( 11:29 352&(66,1',&$725,1$&2035(+(16,9(&$1&(5 (2PRGHR6DOq 4CPS-194 &(175( $6$)(+$1'/,1*+$=$5'286'58*6675$7(*<72 Section 4 ,03529(7+(6$)(7<2)+($/7+352)(66,21$/6 11:37 ,&DxDPDUHV2UELV 4CPS-164 5('8&,1*(;32685(%<0(',&$/35(6&5,37,215(9,(:,1 1856,1*+20(6 Section 5 $1$/<6,62)'58*,17(5$&7,216%(7:((125$/ 11:45 È1DUULOORV0RUD]D 5PSQ-048 $17,1(23/$67,&$*(176$1'&21&855(170(',&$7,216 SYNERGY SATELLITE EVENT THE EAHP INVITES YOU TO ATTEND THE 2020 SYNERGY SATELLITE SESSION: Hospital pharmacists making the difference Biologics in cancer care have enhanced the therapeutic options With the patents set to expire for a number of medications, for clinicians in the management of oncologic therapy. Monoclonal biosimilars therapeutic proteins offer the potential to increase antibodies (mAbs) are employed as targeted treatment and also access to therapies and reEuDe cancer costs for patients to resolve therapy-related hematologic defi ciencies. and healthcare systems. Sponsored by an educational grant from Amgen Wednesday, 25 March 2020 25th Congress of the EAHP 25-27 March 2020 Gothenburg, Sweden 12:00 to 13:30, Hall C Facilitator Despoina Makridaki Presenters Oncology Biosimilars - ongoing challenges for hospital pharmacists Antonio Melo Gouveia Budget impact and cost-effectiveness of oncology biosimilars Steven Simoens* Biosimilars in Oncology: Healthcare and clinical considerations Ioannis Boukovinas* CONTACT US | [email protected] ACPE UAN: 0475-0000-20-005-L04-P. A knowledge based activity. th The European Association of Hospital Pharmacists (EAHP) is accredited by the EAHP CONGRESS Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education SYNERGY SATELLITE EVENT THE EAHP INVITES YOU TO ATTEND THE 2020 SYNERGY SATELLITE SESSION: 25th Congress of the EAHP 25-27 March 2020 Gothenburg, Sweden The Hospital Pharmacist can balance the antithrombotic benefit of the DOAC with its bleeding risk by recommending the appropriate dose of DOACs to physicians according to the patients’ characteristics. The Hospital Pharmacist as part of an antithrombotic stewardship programme needs to ensure adherence to anticoagulant guidelines to maximize the benefit of anticoagulation and minimize the complications. The Hospital Pharmacist’s role in antithrombotic stewardship SPONSORED BY AN EDUCATIONAL GRANT FROM BAYER Facilitator Virgina Silvari Wednesday, 25th March 2020 14.45 to 16.15 room H1 Thursday, 26th March 2020 Presenters Minimising bleeding Antithrombotic stewardship: the proof of risk associated with 08.45 to 10.15 room H1 the pudding... anticoagulation use Paul Wright Patricia Van Den Bemt CONTACT US | [email protected] ACPE UAN: 0475-0000-20-006-L04-P. A knowledge based activity. th The European Association of Hospital Pharmacists (EAHP) is accredited by the EAHP CONGRESS Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education Abstracts Section 1: Introductory Statements and 1ISG-002 BIOLOGICAL DRUGS FOR THE TREATMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS: A COST Governance ANALYSIS AND AN APPLICATION OF A CORRELATION ANALYSIS TO INVESTIGATE COST EFFECTIVENESS 1ISG-001 CAN RIVAROXABAN BECOME COST SAVING 1N Sagaria*, 2D Mengato, 1I Corbucci, 1G Felluga, 2G Morandell, 2ATavella.1School of COMPARED WITH VITAMIN K ANTAGONISTS IN THE Hospital Pharmacy, Department of Pharmaceutical Sciences University of Padova, Padova, TREATMENT OF PATIENTS WITH NON-VALVULAR Italy; 2Bolzano General Hospital, Hospital Pharmacy Department, Bolzano, Italy ATRIAL FIBRILLATION IN FRANCE? 10.1136/ejhpharm-2020-eahpconf.2 1SRobert*,2F Vincent, 3S Vengadessane. 1Chru Nancy, Pharmacy, Vandoeuvre Les Nancy, 2 3 France; Hospices Civils De Lyon, Pharmacie, Lyon, France; Université Paris Descartes, Background and importance The introduction of the first bio- Faculté De Pharmacie De Paris, Paris, France logical drugs has led to a new era for patients. Moreover, the recent arrival of biosimilars has guaranteed effectiveness 10.1136/ejhpharm-2020-eahpconf.1 at a more sustainable cost. We compared the recently Background and importance Non-valvular atrial fibrillation approved biological drugs with biosimilars and older biologi- (NVAF) affects 750 000 people in France and is associated cal molecules, using a new cost effectiveness analysis with significant morbidity, use of healthcare resources and approach. costs. The randomised controlled trial ROCKET-AF demon- Aim and objectives To compare the long term therapy cost strated that rivaroxaban is an efficacious alternative to war- and cost effectiveness of biological systemic therapies for treat- farin in patients with NVAF. The new oral anticoagulants ing patients with moderate to severe plaque psoriasis. (NOAC) appear to have an acceptable cost effectiveness Material and methods We collected therapy costs from our ratio in France. But is it possible that rivaroxaban could internal hospital database. We reported the purchase price, remain cost effective with the introduction of generic including any discounts. Efficacy data, measured with the PASI drugs? index, for 12/16 weeks, was obtained from a recent meta- Aim and objectives To determine the price threshold for rivar- analysis by Sawyer et al. We calculated the long term costs by oxaban to become cost effective compared with vitamin K multiplying the monthly cost for a single patient, including antagonists (VKAs) in the treatment of NVAF, using real the induction phase. Our cost effectiveness analysis was per- world evidence and from a French payer perspective. formed by a correlation analysis between efficacy and the cost Material and methods The annual cost differences associated of therapy for the 12/16 weeks of treatment. We calculated, with rivaroxaban use compared with VKAs among NVAF for each molecule at a different PASI, a correlation index (R) patients were estimated. Clinical events reflecting the efficacy to investigate if a correlation between cost and efficacy could and safety of the drugs were converted into costs. Drugs costs be established. and VKA monitoring were added to obtain a total cost. Cost Results Cost analysis of the first year and the first 3 years of differences were then calculated with a price of rivaroxaban therapy showed how the introduction of biosimilar drugs reduced by: 20% (reduction in the price of the brand name greatly lowered global expenditure.